Application of small molecule compound C2 in preparation of preparation or medicine for treating malignant tumors

By developing small molecule compound C2, the degradation of PD-L1 protein is promoted, and the problems of large side effects and drug resistance of existing antibodies in the treatment of malignant tumors are solved, achieving the effect of significantly inhibiting tumor growth and enhancing immune response.

CN119745853AActive Publication Date: 2025-04-04LIANGZHU LAB
3 Cites 0 Cited by

Patent Information

Application Number
CN202411945761.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-26
Publication Date
2025-04-04
Estimated Expiration
2044-12-26

AI Technical Summary

Technical Problem

The existing anti-PD-L1 monoclonal antibodies have problems such as major side effects and drug resistance when treating malignant tumors, and lack effective small-molecule compounds to promote the degradation of PD-L1 and enhance the tumor immune response.

Method used

The small molecule compound C2 is developed to regulate the tumor immune microenvironment by promoting the degradation of PD-L1 protein, enhancing the infiltration and immune response of CD8+ T cells, thereby inhibiting tumor growth.

Benefits of technology

C2 significantly degrades PD-L1 protein, enhances tumor immune response, significantly inhibits the growth and progress of triple-negative breast cancer, and has good safety and therapeutic effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of a small molecule compound C2 in preparation of a preparation or a medicine for treating malignant tumors. The molecular formula of the small molecule compound C2 is C25H27N3O4S, and the small molecule compound C2 can significantly promote degradation of PD-L1 in triple negative breast cancer cells and enhance tumor immune response. The research on a triple negative breast cancer mouse transplantation tumor model proves that the small molecule compound C2 can obviously enhance the infiltration of immune cells in a tumor microenvironment and inhibit tumor growth, and shows a good treatment effect on malignant tumors.
Need to check novelty before this filing date? Find Prior Art